Free Webex Call
The Global Gynecology Drugs Market was valued at USD14139.56 million in 2021 and is expected to grow at a steady CAGR of 8.64% in the forecast period, 2023-2027, to reach USD21395.67 million by 2027. The market is driven by the increased incidences of gynecological diseases and the rise in the elderly female population. Also, the high-end investments by the public and private players in research and development activities to improve the effectiveness of drugs and eliminate the side effects are expected to create lucrative growth opportunities for the Global Gynecology Drugs Market in the forecast period. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The rise in the female old age population is expected to fuel the demand for gynecology drugs as they are more prone and are at higher risk of getting affected by gynecological disorders. According to the World Population Prospects in 2021, about 9.5% of females above the age group of 60 years are vulnerable to getting affected by gynecological disorders. The growing old-age population is expected to fuel the demand for the Global Gynecology Drugs Market in the forecast period.
The Global Gynecology Drugs Market is segmented into therapeutics, indication, distribution channel, regional distribution, and competitive landscape. Based on regional distribution, the North American region dominated the market in 2021 and held 35.09% of the overall market share. The presence of major market players and well-developed healthcare infrastructure are the primary drivers for the gynecology drugs market. Also, the increased prevalence of breast cancer, menopausal disorders, busy lifestyles, and high stress in women is accelerating the demand for gynecology drugs.
Major companies operating in the Global Gynecology Drugs Market are Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals, amongst others.
Years considered for this report:
Historical Years: 2017-2020Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023-2027
Objective of the Study:
- To analyze the historical growth and the market size of the Global Gynecology Drugs Market from 2017 to 2021.
- To estimate and forecast the market size of the Global Gynecology Drugs Market from 2023 to 2027 and growth rate until 2027.
- To classify and forecast the Global Gynecology Drugs Market is divided into therapeutics, indication, distribution channel, regional distribution, and competitive landscape.
- To identify drivers and challenges for the Global Gynecology Drugs Market.
- To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the Global Gynecology Drugs Market.
- To conduct pricing analysis for the Global Gynecology Drugs Market.
- To identify and analyze the profile of leading players operating in the Global Gynecology Drugs Market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of leading gynecology drugs manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the gynecology drugs manufacturers who could not be identified due to the limitations of secondary research. The publisher Research analyzed the gynecology drugs manufacturers, distribution channels and presence of all major players operating in the Global Gynecology Drugs Market all over the world.
The publisher calculated the Global Gynecology Drugs Market size by using a bottom-up approach, where data for various regions was recorded and forecasted for the future years. The publisher Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the publisher.
Key Target Audience:
- Gynecology drugs manufacturers/suppliers/distributors
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances related to gynecology drugs
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as gynecology drugs manufacturers, suppliers, distributors, and other stakeholders. The report would enable the stakeholders in strategizing investments and capitalizing on emerging market opportunities.
Report Scope:
In this report, the Global Gynecology Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Gynecology Drugs Market, By Therapeutics:
- Non-Hormonal Therapy
- Hormonal Therapy
Gynecology Drugs Market, By Indication:
- Contraception
- Gynecology Infections
- Female Infertility
- Postmenopausal disorders
- Polycystic Ovary Syndrome
- Osteoporosis
- Gynecology Cancers
- Endometriosis
- Others (Urogenital Malformation, UTI & others)
Gynecology Drugs Market, By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Gynecology Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Gynecology Drugs Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:Company Information
Detailed analysis and profiling of additional market players (up to five).Please note: With the Enterprise license, the PDF product is printable and editable and comes with a market data excel sheet.
Frequently Asked Questions about the Global Gynecology Drugs Market
What is the estimated value of the Global Gynecology Drugs Market?
What is the growth rate of the Global Gynecology Drugs Market?
What is the forecasted size of the Global Gynecology Drugs Market?
Who are the key companies in the Global Gynecology Drugs Market?
Report Attribute | Details |
---|---|
No. of Pages | 199 |
Published | July 2022 |
Forecast Period | 2017 - 2027 |
Estimated Market Value ( USD | $ 11581.23 Million |
Forecasted Market Value ( USD | $ 21395.67 Million |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |
Table of Contents
1. Product Overview2. Research Methodology3. Executive Summary5. Impact of COVID-19 on Global Gynecology Drugs Market13. Market Trends and Developments15. Strategic Recommendations
4. Voice of Customer
6. Global Gynecology Drugs Market Outlook
7. North America Gynecology Drugs Market Outlook
8. Europe Gynecology Drugs Market Outlook
9. Asia Pacific Gynecology Drugs Market Outlook
10. South America Gynecology Drugs Market Outlook
11. Middle East and Africa Gynecology Drugs Market Outlook
12. Market Dynamics
14. Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
A selection of companies mentioned in this report includes:
- Eli Lilly and Company Ltd.
- Pfizer Inc.
- Merck & Co., Inc.
- Amgen Inc.
- AstraZeneca Plc
- F. Hoffmann-La Roche Ltd.
- Allergan Plc.
- Bayer AG
- Abbott Laboratories Ltd.
- AbbVie Inc.
- GlaxoSmithKline Plc
- Novartis Ltd.
- Lupin Pharmaceuticals, Inc.
- Johnson and Johnson Inc.
- Sanofi SA